Best Practices in Improving Diagnosis and Treatment of Neurotrophic Keratitis (CME/CE Symposium)

Seattle, WA US
May 7, 2024

To register for the symposium, click the purple "Take Course" button. (Please be sure to be logged in)

Tuesday, May 7, 2024
6:00 PM – 6:30 PM PT Onsite Registration and Dinner
6:30 PM –
8:00 PM PT CME/CE Symposium

Sheraton Grand Seattle
Grand Ballroom D, 2nd Floor

1400 Sixth Avenue
Seattle, Washington

This educational symposium is not affiliated with the official program of ARVO 2024.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Integrate corneal sensitivity testing into practice to identify neurotrophic keratitis
  • Select appropriate treatment for patients with neurotrophic keratitis using clinical evidence
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 COPE
  • 1.50 Participation
Course opens: 
05/07/2024
Course expires: 
08/07/2024
Event starts: 
05/07/2024 - 9:30pm EDT
Event ends: 
05/07/2024 - 11:00pm EDT
Sheraton Grand Seattle
1400 Sixth Avenue
Grand Ballroom D, 2nd Floor
Seattle, WA 98101
United States
+1 (888) 236-2427

Faculty

Francis S. Mah, MD (Chair)
Director, Cornea and External Diseases
Co-Director, Refractive Surgery
Scripps Clinic Medical Group
La Jolla, California

Douglas K. Devries, OD
Co-Founder
Eye Care Associates of Nevada
Sparks, Nevada

Lisa M. Nijm, MD, JD
Assistant Professor of Ophthalmology
University of Illinois Eye and Ear Infirmary
Chicago, Illinois
Founder and Medical Director
Warrenville EyeCare and LASIK Center
Warrenville, Illinois

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Faculty

Douglas K. Devries, OD, is a consultant for AbbVie Inc, Alcon, Avellino, Azura Ophthalmics, Bausch Health, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharma Inc, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch Health, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.

Lisa M. Nijm, MD, JD, is a consultant for AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Nordic Pharma, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Trukera, and Visus Therapeutics; is an advisory board member of AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, and Trukera; is on the speakers bureau for AbbVie Inc, Amgen Inc, Bausch & Lomb Incorporated, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options that have not been exercised in Trukera.

Francis S. Mah, MD, is a consultant for Dompé US, Inc*, Kala Pharmaceuticals, and Kiora Pharmaceuticals, Inc*; and is an advisory board member of San Diego Eye Bank.

* The financial relationship existed during the last 24 months but has now ended

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 91290-TD (Synchronous In Person)
COPE Course Category: Treatment & Management of Ocular Disease
Administrator:

This activity, COPE Activity Number 128385, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.

The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.

This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 322.1

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 COPE
  • 1.50 Participation
Please login or register to take this course.

Please login if you already have an account on the MedEdicus Learning Portal OR register to create an account and sign up for this symposium.

We look forward to seeing you in Seattle on May 7!

If you do not receive an email confirmation, please check your spam folder or email info@mededicus.com.